# Protalix BioTherapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2016

- Company: [Protalix BioTherapeutics, Inc.](/companies/plx.md) (CIK 1006281)
- Form: 10-Q
- Filed: 2016-05-09
- Accepted by EDGAR: May 9, 2016, 16:32 ET
- Period: 2016-03-31
- Accession: 0001144204-16-099933
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1006281/000114420416099933/v438545_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1006281/000114420416099933/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2016-01-01 to 2016-03-31 | $679.0k | us-gaap:Revenues |
| Cost of revenue | 3 months, 2016-01-01 to 2016-03-31 | $523.0k | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2016-01-01 to 2016-03-31 | $156.0k | us-gaap:GrossProfit |
| Research and development | 3 months, 2016-01-01 to 2016-03-31 | $7.3m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2016-01-01 to 2016-03-31 | $2.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2016-01-01 to 2016-03-31 | −$7.9m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2016-01-01 to 2016-03-31 | −$8.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2016-01-01 to 2016-03-31 | −$0.09 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months, 2016-01-01 to 2016-03-31 | −$9.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2016-01-01 to 2016-03-31 | $251.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2016-03-31 | $66.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-03-31 | $76.3m | us-gaap:AssetsCurrent |
| Total assets | at 2016-03-31 | $87.3m | us-gaap:Assets |
| Current liabilities | at 2016-03-31 | $9.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2016-03-31 | $84.7m | us-gaap:Liabilities |
| Shareholders' equity | at 2016-03-31 | $2.6m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1006281/000114420416099933/v438545_10q.htm

Filed May 9, 2016.
Source: SEC EDGAR, the filing index for accession 0001144204-16-099933. Last ingested by Listed: Nov 10, 2026, 16:48 ET. No prices; not investment advice.
